The overall mortality was 11.5%; the non-survivors revealed significantly higher d-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time compared to survivors on admission (P < .05); 71.4% of non-survivors and 0.6% survivors met the criteria of disseminated intravascular coagulation during their hospital stay. The gene discussed is F2; the disease is Disseminated intravascular coagulation.